{"links":{"html":"https://www.erudio.com/reports/calgb-10403-nct00558519","json":"https://www.erudio.com/reports/calgb-10403-nct00558519.json","markdown":"https://www.erudio.com/reports/calgb-10403-nct00558519.md","mcp":{"server":"https://mcp.erudio.com/mcp","tool":"get_report_card","arguments":{"slug":"calgb-10403-00558519"}},"request":"https://www.erudio.com/contact?report=calgb-10403-00558519"},"offer":{"cited_commentary_sources":28,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a licence key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, to join with NPI-keyed systems such as a CRM. Every report already names and describes its speakers.","available_with":"12-month updates","cap_usd":1250,"identity_verified_people":36,"optional":true,"price_per_verified_person_usd":15,"price_usd":540,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":1250,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One licence key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_tools":["create_order","get_order","recover_key"],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"calgb-10403-nct00558519"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the licence key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=calgb-10403-00558519","people":"Tom and Audun, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/calgb-10403-nct00558519","renewal":"Subscriptions are prepaid and do not renew automatically.","terms":"https://www.erudio.com/terms"},"size":"standard","updates_usd":{"3_months":2200,"6_months":3100,"12_months":4400},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-08T06:48:21.724185Z","notify_subscribers":false,"status":"corrected","summary":"taxonomy mapping corrected"},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":13,"no_commentary_found":0},"aspects":[{"claim_count":39,"coverage":"discussed","id":"A1","source_count":5,"title":"CR1 continuation versus transplant after pediatric induction"},{"claim_count":34,"coverage":"discussed","id":"A2","source_count":8,"title":"Blinatumomab integration, alternative backbones, cycle number and maintenance"},{"claim_count":48,"coverage":"discussed","id":"A3","source_count":8,"title":"MRD sensitivity, sampling, response kinetics and decision timing"},{"claim_count":39,"coverage":"discussed","id":"A4","source_count":3,"title":"Asparaginase completion, reactions, silent inactivation and formulation switching"},{"claim_count":34,"coverage":"discussed","id":"A5","source_count":3,"title":"Toxicity-specific reasons to continue, recover, rechallenge or discontinue"},{"claim_count":43,"coverage":"discussed","id":"A6","source_count":7,"title":"Age and BMI selection, dosing adaptations and toxicity susceptibility"},{"claim_count":30,"coverage":"discussed","id":"A7","source_count":4,"title":"CNS protection with add-on, substitution and early transplant sequences"},{"claim_count":36,"coverage":"discussed","id":"A8","source_count":6,"title":"Bispecific safety, administration, routine-care exceptions and support"},{"claim_count":29,"coverage":"discussed","id":"A9","source_count":3,"title":"Resource-adapted CALGB 10403 and the implementation learning curve"},{"claim_count":37,"coverage":"discussed","id":"A10","source_count":4,"title":"Equity, sustainable testing, AYA services and referral capability"},{"claim_count":26,"coverage":"discussed","id":"A11","source_count":8,"title":"Long-term durability, late events and T-ALL-specific uncertainties"},{"claim_count":17,"coverage":"discussed","id":"A12","source_count":4,"title":"Relapse phenotype and treatment options after frontline CD19 exposure"},{"claim_count":47,"coverage":"discussed","id":"A13","source_count":10,"title":"Conditional de-escalation, subcutaneous delivery and research consolidation"}],"counts":{"cited_sources":28,"claims_by_expression_type":{"comparison":157,"experience":164,"interpretation":197,"opinion":148,"primary_context":4,"question":117,"restatement":135,"uncertainty":80,"unspecified":63},"claims_by_kind":{"attributed_opinion":27,"interpretation":40,"limitation":22,"source_observation":976},"evidence_units":523,"findings":13,"people_cited":38,"people_identity_verified":36,"people_total":47,"screened_sources":41,"verified_claims":1065},"depth":"standard","depth_rule":"thin if verified claims <30, findings <5, or cited sources <10; rich if verified claims >=100, findings >=8, and cited sources >=30; otherwise standard","findings_index":[{"id":"F1","title":"MRD-negative remission does not settle the CR1 transplant decision, particularly with adverse genetics"},{"id":"F2","title":"Blinatumomab enthusiasm does not resolve which backbone to retain or how far to extrapolate E1910"},{"id":"F3","title":"MRD is discussed as an assay- and regimen-dependent trajectory, not a binary result"},{"id":"F4","title":"Maintaining asparaginase exposure requires distinguishing reactions, inactivation and safe switching"},{"id":"F5","title":"Exposure preservation has toxicity-specific limits: stopping, holding and rechallenging are not interchangeable"},{"id":"F6","title":"Age, obesity and formulation drive dosing questions, but observational risk is not proof of a modifiable survival effect"},{"id":"F7","title":"Adding blinatumomab is not the same CNS-risk question as replacing chemotherapy"},{"id":"F8","title":"Manageable bispecific toxicity still requires expertise, delivery support and selective withholding"},{"id":"F9","title":"Modified CALGB 10403 is described as feasible in Mexico and Guatemala, conditional on infrastructure and a learning curve"},{"id":"F10","title":"Access and AYA support determine which evidence-based choices are real options"},{"id":"F11","title":"Long-term CALGB 10403 discussion qualifies early optimism and keeps T-ALL distinct"},{"id":"F12","title":"Earlier CD19 targeting raises a relapse-phenotype question, not an established frontline CD19-loss rate"},{"id":"F13","title":"De-escalation, new delivery routes and CAR T are attractive, but their conditions remain explicit"}],"medical_affairs_question":"What evidence would clinicians need to integrate genotype, the depth and timing of MRD clearance, transplant harm and monitoring capability into a shared CR1 decision framework?","sections":{"analysis":[{"id":"section-1","level":2,"title":"MRD-negative remission does not settle the CR1 transplant decision"},{"id":"section-2","level":2,"title":"Blinatumomab enthusiasm does not resolve which backbone to retain"},{"id":"section-3","level":2,"title":"MRD is an assay- and regimen-dependent trajectory"},{"id":"section-4","level":2,"title":"Maintaining asparaginase exposure requires correct reaction assessment"},{"id":"section-5","level":2,"title":"Exposure preservation has toxicity-specific limits"},{"id":"section-6","level":2,"title":"Dosing, obesity and ethnicity require separate interpretation"},{"id":"section-7","level":2,"title":"CNS protection depends on whether chemotherapy is added to or replaced"},{"id":"section-8","level":2,"title":"Manageable bispecific toxicity requires expertise and selective exceptions"},{"id":"section-9","level":2,"title":"Modified CALGB 10403 feasibility is resource- and infrastructure-dependent"},{"id":"section-10","level":2,"title":"Access and AYA support determine which options are achievable"},{"id":"section-11","level":2,"title":"Long-term follow-up qualifies early optimism and keeps T-ALL distinct"},{"id":"section-12","level":2,"title":"Earlier CD19 targeting leaves an unanswered relapse-phenotype question"},{"id":"section-13","level":2,"title":"De-escalation and new delivery approaches remain conditional directions"},{"id":"section-14","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, na, single group, phase2"},"identity":{"accepted_at":"2026-10-08T06:48:21.724185Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-07T22:54:07Z","record_hash":"67f7503b95922f9b38848399d321cbc796c12a98c13f147fca00786bf9cf7159","release_hash":"248afa050b6fd3a9af4e8672660f219a982be39d381bbd576c31b4cb02d8aef6","report_id":"erudio-nct00558519","run_id":"2b7ff00d-5bb1-4427-8f17-9291a8a0e8e2","schema_version":"5.0","slug":"calgb-10403-00558519","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"CALGB 10403 discussions ask how blinatumomab should fit into pediatric-inspired treatment for adolescents and young adults with newly diagnosed B-cell acute lymphoblastic leukemia. Other topics include residual-disease testing and timing, transplant in first remission, asparaginase reactions and exposure, age- and BMI-related dosing, CNS protection, relapse phenotype, treatment duration, and long-term follow-up. Discussions also address T-cell disease, administration logistics, drug and testing access, referral pathways, and patient support. The account draws on supplied podcasts, videos, and X threads.","meta_description":"41 HCP sources screened · 1065 verified claims from 28 sources · 13 findings. Updated 2026-10-08.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-9aeaf7a084bb1c23f212","claim-40a3ff315fea22efe3fb"],"id":"F2","paraphrase":"A podcast speaker asked how blinatumomab could be incorporated into pediatric-inspired therapy and whether adding it benefits patients with MRD undetectable by next-generation sequencing.","source_channel":"podcast","source_date":"2024-12-22","title":"Blinatumomab enthusiasm does not resolve which backbone to retain or how far to extrapolate E1910"},{"cited_claim_ids":["claim-50a9467050df922c52ea"],"id":"F12","paraphrase":"An audience member in a podcast panel asked about the frequency of CD19-negative relapse after frontline blinatumomab consolidation given during MRD-negative remission.","source_channel":"podcast","source_date":"2026-01-14","title":"Earlier CD19 targeting raises a relapse-phenotype question, not an established frontline CD19-loss rate"}]},"publication":{"approved_at":"2026-10-07T22:54:07Z","approved_by":"Audun Utengen","corrections":[{"affected_ids":[],"date":"2026-10-08T20:30:00Z","summary":"Duplicate cards for the same person were combined"},{"affected_ids":[],"date":"2026-10-09T20:08:00Z","summary":"taxonomy mapping corrected"}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"1.0","scope_and_limits":{"commentary_scope":{"basis":"Reviewed retained sources only; not all HCPs or all public discussion.","empty_source_ids":[],"has_known_gaps":true,"held_out_finds":20,"refresh_due_at":"2026-10-09T06:48:21.724185Z","retrieval_gaps":["commentary:coverage_scope:keyword matches to trial identifier and registry aliases; single-letter acronym variants require planned context in the same indexed chunk; unnamed references or other transcription variants may be absent","commentary:indexed_source_unreadable:podcast:episode_id:0a6978:SourceAcquisitionError:Erudio MCP fetch_source_transcript rejected the source request","commentary:indexed_source_unreadable:podcast:episode_id:828815:SourceAcquisitionError:Erudio MCP fetch_source_transcript rejected the source request","commentary:indexed_source_unreadable:podcast:episode_id:8572ba:SourceAcquisitionError:Erudio MCP fetch_source_transcript rejected the source request","commentary:held_out:mcp:youtube:bSAKyQw52KY@33625:34521: The replacement for a claim identifies the regimen as blinatumomab, but the supplied passage only contains the unresolved rendering “Blinaponatib.” This context does not establish that blinatumomab alone is the intended regimen, so the normalization assigns the CNS-progression observation to an unproven treatment.","commentary:held_out:mcp:youtube:8qcykzz6-Qo@28318:29721: a claim assigns the rechallenge phrase to Maese as a personal management preference. The surrounding audience-poll language, including “No people picked that one,” leaves that ownership unresolved. a claim appropriately preserves the ambiguity in the parallel recording.","commentary:held_out:mcp:youtube:bSAKyQw52KY@14276:16029,mcp:youtube:bSAKyQw52KY@14093:14274: a claim says the group whose prognosis is discussed is unidentified. mcp:youtube:bSAKyQw52KY@14093:14274 immediately asks about MRD-negative patients who do not receive blinatumomab, establishing the comparison's population and treatment context.","commentary:held_out:mcp:youtube:bSAKyQw52KY@14276:16029,mcp:youtube:ym5qXfpl-4I@14530:16308: a claim and a claim describe the basis of the high-risk classification as unspecified. In both original units, Shah explicitly clarifies that the risk being discussed is genomic risk, then distinguishes a separate age-related risk category. Leaving the 30% estimate as generic high risk loses this material qualification.","commentary:held_out:mcp:podcast:5d4f9e@59632:60961,mcp:youtube:feCX1vCqb2o@61680:63086: a claim definitively assigns the “excellent outcomes” remark to patients remaining MRD-positive; a claim definitively assigns it to patients becoming negative. The final pronoun in the supplied speech does not unambiguously establish that distinction. The report repeats the positive-group assignment as a settled qualification.","commentary:held_out:mcp:youtube:6MOlRUXnE6Q@54739:54851,mcp:youtube:6MOlRUXnE6Q@54853:54935,mcp:youtube:6MOlRUXnE6Q@54937:55245: a claim retains only a nonspecific statement that the agents had never been compared. mcp:youtube:6MOlRUXnE6Q@54937:55245 completes the interrupted sentence as “head-to-head in the first-line setting.” Omitting that boundary makes the comparison caveat broader than the original exchange.","commentary:held_out:mcp:youtube:8qcykzz6-Qo@10230:12971,mcp:youtube:8qcykzz6-Qo@7661:10228: a claim calls the formulation replaced by calaspargase unidentified. The adjacent mcp:youtube:8qcykzz6-Qo@7661:10228 discussion explicitly identifies pegaspargase as the original pegylated E. coli product and the preceding workhorse, resolving “that.” The current uncertainty loses the object of Rau's formulation-selection account.","commentary:held_out:mcp:youtube:8igiA3DgKiI@52275:54189,mcp:youtube:8igiA3DgKiI@49816:52273: a claim leaves the regimen in Bellomo's heart-failure comment unidentified. mcp:youtube:8igiA3DgKiI@49816:52273 immediately names mini-Hyper-CVAD plus inotuzumab and states that the anthracycline is removed. That supplied context establishes the treatment she calls a good option.","commentary:held_out:mcp:youtube:feCX1vCqb2o@78711:78821,mcp:youtube:feCX1vCqb2o@78440:78630,mcp:youtube:feCX1vCqb2o@77455:78438: a claim says the cited exchange does not specify a relapse subtype. mcp:youtube:feCX1vCqb2o@77455:78438 explicitly discusses CD19 loss and asks for the overall rate; mcp:youtube:feCX1vCqb2o@78440:78630 supplies the relapsing-responder denominator. The approximately 10% estimate should not be exported as an unspecified relapse estimate.","commentary:held_out:mcp:youtube:8igiA3DgKiI@61610:63577: Bellomo's distinct access-dependent reason for initial TKI choice is absent from the verified claims and their quotations: her hospital has only dasatinib readily available, while outpatient ponatinib approval and acquisition can require a week or two, by which time the team wants to start treatment. Generic insurance and high-white-count access claims do not retain this operational constraint.","commentary:held_out:mcp:podcast:e985a5@56162:56683: The exchange about using blinatumomab without rapid MRD assessment contains a distinct retained-scope view absent from all verified claims: an unidentified speaker says use is not restricted to MRD-positive patients while still encouraging MRD assessment to inform transplant decisions.","commentary:held_out:mcp:podcast:e985a5@58366:59143: The unidentified respondent's access-dependent treatment approach is absent from all verified claims: start blinatumomab while obtaining and tracking MRD rather than waiting for the result, then move to CAR T, transplant or another approach if MRD remains positive after two cycles."],"source_count":41,"unreadable_unit_ids":[]},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Sources were found by searching for the trial's name, registry number and known aliases. Discussion that refers to the trial without naming it may be missing.","20 points raised by the independent review are not yet resolved in this edition, such as a clinician view not yet captured as evidence or a qualifier to restore. The next refresh takes them up.","3 further source limits are recorded in the machine-readable scope of this record.","The material is not a representative sample of HCPs or all public discussion. Multiple versions of the same conversation do not increase the number of independent clinical opinions.","Three indexed podcast sources could not be read. Searches focused on trial identifiers and registry aliases may miss unnamed references, acronym variants or different transcription renderings.","An unclear treatment name prevents attributing one CNS-progression observation to a specific regimen; it is not used to claim a blinatumomab-specific finding.","Full text was unavailable for two linked publications. Their abstracts provide context but cannot independently resolve every detailed study assertion made by speakers.","No separate protocol document was available beyond registry material, and regulatory material covered only part of the intervention-related records. Speaker claims about approvals or guidelines remain attributed claims, not independent regulatory conclusions.","Many discussions concern age extensions, LBL, Ph-positive alternatives, post-transplant monitoring or research consolidation. Those settings are not treated as results or universal rules for the original CALGB 10403 population.","Some source names or professional roles are incompletely established. Identity context does not identify an otherwise unnamed passage or give a view additional evidentiary weight.","Posting dates do not establish when a session occurred or show that a clinician changed position across settings."]},"sources":{"cited_sources":{"by_channel":{"other":0,"podcast":9,"publication":0,"registry":0,"regulatory":0,"x_thread":9,"x_video":0,"youtube":10},"by_evidence_role":{"commentary":28},"count":28,"evidence_window":{"end":"2026-09-10","start":"2021-09-14"},"retrieval_snapshot":"2026-10-08T05:28:46.771029Z","timeline":[{"count":1,"week":"2021-W37"},{"count":1,"week":"2022-W11"},{"count":1,"week":"2023-W11"},{"count":1,"week":"2023-W13"},{"count":1,"week":"2023-W14"},{"count":2,"week":"2023-W24"},{"count":1,"week":"2023-W38"},{"count":2,"week":"2024-W05"},{"count":1,"week":"2024-W08"},{"count":1,"week":"2024-W27"},{"count":1,"week":"2024-W49"},{"count":1,"week":"2024-W51"},{"count":1,"week":"2025-W24"},{"count":1,"week":"2025-W28"},{"count":1,"week":"2025-W31"},{"count":1,"week":"2025-W36"},{"count":2,"week":"2026-W02"},{"count":1,"week":"2026-W03"},{"count":1,"week":"2026-W10"},{"count":2,"week":"2026-W11"},{"count":1,"week":"2026-W18"},{"count":2,"week":"2026-W22"},{"count":1,"week":"2026-W28"},{"count":1,"week":"2026-W37"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT00558519:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT00558519:results","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT00558519:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:30658992","quote_policy":"short_quote_link_out"},{"id":"pubmed:33496745","quote_policy":"short_quote_link_out"},{"id":"openfda:c961a1ac-6705-4756-9abc-9d84a6fcb5c8:20260903","quote_policy":"short_quote_link_out"},{"id":"openfda:7ea701ce-e7d3-4349-a9c2-642a501d45c8:20260130","quote_policy":"short_quote_link_out"},{"id":"openfda:9705fa12-499e-41a3-8fb4-f6df0858b851:20260119","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:2fce72","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:48975a","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:4b42d2","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:5d4f9e","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:80c887","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:8b4865","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:a6f175","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:bbe61d","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:e985a5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1437547071079337985:cdfc2a35-73c3-4c43-97ba-ad44b1e1b716","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1504295741157687296:4dfa6a66-8723-4eb4-a993-1b2eabb62202","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1640351504555995136:629d11c5-a6fb-4568-9f77-06fc843022a0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1642527731022741509:ab1796b3-092d-4936-a830-38922397248d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1650489216550273025:501eb98a-25ce-4698-a0b2-6448fe60a6ed","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1668762737114226693:87e37400-7dc8-4a0c-8637-042f79fbf1b7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1668818420647772163:fffe6421-b1d6-4414-a092-d8c44deac299","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1677851466143518720:e7136e87-521c-4ef1-9de5-3950aa32257c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1734376951748628719:caf66336-7f1f-4cf8-9703-fce757e8f3ad","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1761068989361315873:e61717eb-72b1-45d5-b682-74845ed011aa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1808523273753502031:89fde126-0ecc-4061-95a3-f351cee1d24f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1824839766040289572:02d5e0c5-b6fc-4f2a-b8ac-f12ff48f9ecc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1919505705985266117:6b08213a-fffd-47c0-88a2-ddf00dc4c0b5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1919506189437567322:19346325-c2d4-456b-ab92-4b72536a8cc1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1932858594439147991:ef398c8c-b795-4d1f-be62-25cd06800df9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1933618123648733295:2de58bf8-784f-4cfd-b668-2acb215d3ab1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1949187807651733746:ca2c745b-30f0-432a-a30f-762e7be8d129","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1971672312056254545:3d75813d-5f6f-4301-8b2d-15143632d009","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1971676595720278294:f36d044b-bbff-4f80-8040-3a417b1c3c08","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1978204778652975411:11574b8c-f3a2-451d-ae5f-ff115020ead1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098019901562585476:f69a48e8-743b-470d-a590-a3214bfdf133","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098129932404609051:c6183c87-1151-470a-b605-823a5c1457a2","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:4TXMi7Q9ydc","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:6MOlRUXnE6Q","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:8igiA3DgKiI","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:8qcykzz6-Qo","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:YB189NGzfjo","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:bSAKyQw52KY","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:feCX1vCqb2o","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:rLJdu6atjrU","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:tUFI4mt8d4U","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:ym5qXfpl-4I","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"other":0,"podcast":9,"publication":0,"registry":0,"regulatory":0,"x_thread":22,"x_video":0,"youtube":10},"by_evidence_role":{"commentary":41},"count":41,"evidence_window":{"end":"2026-09-10","start":"2021-09-14"},"retrieval_snapshot":"2026-10-08T05:28:46.771029Z","timeline":[{"count":1,"week":"2021-W37"},{"count":1,"week":"2022-W11"},{"count":1,"week":"2023-W11"},{"count":2,"week":"2023-W13"},{"count":2,"week":"2023-W14"},{"count":1,"week":"2023-W17"},{"count":2,"week":"2023-W24"},{"count":1,"week":"2023-W27"},{"count":1,"week":"2023-W38"},{"count":1,"week":"2023-W50"},{"count":2,"week":"2024-W05"},{"count":1,"week":"2024-W08"},{"count":1,"week":"2024-W27"},{"count":1,"week":"2024-W33"},{"count":1,"week":"2024-W49"},{"count":1,"week":"2024-W51"},{"count":2,"week":"2025-W19"},{"count":2,"week":"2025-W24"},{"count":1,"week":"2025-W28"},{"count":1,"week":"2025-W30"},{"count":1,"week":"2025-W31"},{"count":1,"week":"2025-W36"},{"count":2,"week":"2025-W39"},{"count":1,"week":"2025-W42"},{"count":2,"week":"2026-W02"},{"count":1,"week":"2026-W03"},{"count":1,"week":"2026-W10"},{"count":2,"week":"2026-W11"},{"count":1,"week":"2026-W18"},{"count":2,"week":"2026-W22"},{"count":1,"week":"2026-W28"},{"count":2,"week":"2026-W37"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"brand_names":{"reason":"No checked-in brand mapping.","status":"unmapped"},"label":"cyclophosphamide","slug":"cyclophosphamide"},{"reason":"Unmapped registry intervention: cytarabine","status":"unmapped"},{"reason":"Unmapped registry intervention: daunorubicin hydrochloride","status":"unmapped"},{"brand_names":{"reason":"No checked-in brand mapping.","status":"unmapped"},"label":"dexamethasone","slug":"dexamethasone"},{"reason":"Unmapped registry intervention: doxorubicin hydrochloride","status":"unmapped"},{"reason":"Unmapped registry intervention: mercaptopurine","status":"unmapped"},{"reason":"Unmapped registry intervention: methotrexate","status":"unmapped"},{"reason":"Unmapped registry intervention: pegaspargase","status":"unmapped"},{"reason":"Unmapped registry intervention: thioguanine","status":"unmapped"},{"reason":"Unmapped registry intervention: vincristine sulfate","status":"unmapped"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Leukemia","slug":"leukemia"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"aliases":["Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","An Intergroup Phase II Clinical Trial for Adolescents and Young Adults With Untreated Acute Lymphoblastic Leukemia (ALL)"],"brief_title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","collaborators":["National Cancer Institute (NCI)"],"conditions":["Leukemia"],"enrollment":{"count":318,"type":"ACTUAL"},"excluded_lookalike_trials":{"reason":"No owner-reviewed lookalike exclusion list.","status":"not_set"},"interventions":[{"name":"cyclophosphamide","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"cytarabine","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"daunorubicin hydrochloride","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"dexamethasone","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"doxorubicin hydrochloride","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"mercaptopurine","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"methotrexate","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"pegaspargase","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"thioguanine","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"vincristine sulfate","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"radiation therapy","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"RADIATION"}],"nct_id":"NCT00558519","official_title":"An Intergroup Phase II Clinical Trial for Adolescents and Young Adults With Untreated Acute Lymphoblastic Leukemia (ALL)","overall_status":"COMPLETED","phase":["PHASE2"],"primary_completion_date":{"date":"2016-09","type":"ACTUAL"},"primary_endpoints":[{"description":"Complete response rate is defined as the percentage of patients who achieve bone marrow response (defined using the M bone marrow criteria for acute lymphoblastic leukemia (ALL); if M0 to M1 status (blast cells ,5%) was achieved by the end of induction or extended induction, the patient was considered a responder) at the end of induction therapy.","measure":"Complete Response Rate","timeFrame":"Up to 8 years post-registration"},{"description":"EFS was defined as time from registration in this study to the earliest occurrence of any of the following: failure to achieve bone marrow response (defined using the M bone marrow criteria for acute lymphoblastic leukemia (ALL); if M0 to M1 status (blast cells ,5%) was achieved by the end of induction or extended induction, the patient was considered a responder) by day 60, death, relapse at any site, or development of second malignant disease.","measure":"Event-free Survival","timeFrame":"Up to 8 years post-registration"},{"description":"DFS was defined as time from bone marrow response in this study to the earliest occurrence of any of the following: failure to achieve bone marrow response (defined using the M bone marrow criteria for acute lymphoblastic leukemia (ALL); if M0 to M1 status (blast cells ,5%) was achieved by the end of induction or extended induction, the patient was considered a responder) by day 60, death, relapse at any site, or development of second malignant disease.","measure":"Disease-free Survival","timeFrame":"Up to 8 years post-registration"},{"description":"OS was defined from registration to death resulting from any cause.","measure":"Overall Survival","timeFrame":"Up to 8 years post-registration"},{"description":"The number of participants who experienced toxicity (defined as at least one grade 3 or higher adverse event at least possibly related to treatment) is reported below.","measure":"Number of Participants Who Experienced at Least One Grade 3 or Higher Adverse Event at Least Possibly Related to Treatment (Toxicity)","timeFrame":"Up to 10 years post-registration"}],"registry_last_updated":"2026-04-29","registry_url":"https://clinicaltrials.gov/study/NCT00558519","short_name":"CALGB-10403","short_name_basis":"sponsor_study_id","sponsor":"Alliance for Clinical Trials in Oncology","start_date":{"date":"2008-03-12","type":"ACTUAL"},"study_design":"interventional, na, single group, phase2","study_ids":[{"id":"CALGB-10403","type":"sponsor_study_id"},{"id":"ECOG C10403","type":"other"},{"domain":"NCI Physician Data Query","id":"CDR0000574230","type":"registry"}],"study_type":"INTERVENTIONAL"}}}